ProfileGDS5678 / 1424839_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 47% 40% 47% 64% 48% 34% 42% 36% 52% 46% 52% 54% 48% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1490147
GSM967853U87-EV human glioblastoma xenograft - Control 22.928240
GSM967854U87-EV human glioblastoma xenograft - Control 33.1155947
GSM967855U87-EV human glioblastoma xenograft - Control 43.8564464
GSM967856U87-EV human glioblastoma xenograft - Control 53.0979648
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8407234
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0328542
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.8074836
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2361652
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0593746
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2583352
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.291154
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.15448
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1953450